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Summary 
Previous studies from this laboratory have demonstrated that Mycobacterium leprae, an obligate 
intracellular bacterial parasite, enters human mononudear phagocytes via complement receptors 
on these host cells and bacterium-bound C3. The present study investigates the role ofM. leprae 
surface molecules in C3 fixation and phagocytosis. By enzyme-linked immunosorbent assay, C3 
binds sdectively to phenolic glycolipid-1 (PGL-1), a major surface molecule of the leprosy badUus. 
C3 fixation to PGL-1 is serum concentration dependent and is abolished in heat-inactivated serum 
or serum containing ethylenediaminetetraacetic  acid.  C3 fixation  is also abolished  in serum 
containing ethyleneglycol-bis (~-aminoethyl ether)N,N,N'-tetraacetic  acid and MgCh indicating 
that isolated PGbl fixes C3 via the classical complement pathway.  The capacity of PGL-1 to 
fix C3 is dependent upon its terminal trisaccharide since sequential removal of monosaccharide 
units of the trisaccharide results in a stepwise reduction in C3 fixation. Deacylation of PGIr 
also abolishes C3 fixation.  C3 fixes to the trisaccharide of PGbl that is chemically linked to 
bovine serum albumin via the chemical carrier, 8-methoxycarbonyloctanol.  PGbl mediates C3 
fixation to polystyrene microspheres, and PGbl and C3 together mediate ingestion of polystyrene 
microspheres by human monocytes, wherein these inert test particles reside in membrane-bound 
phagosomes. Thus, complement receptors on mononuclear phagocytes, complement component 
C3, and PGbl comprise a three-component receptor-ligand-acceptor molecule system for mediating 
phagocytosis  of M.  leprae. 
Ycobacterium leprae is  an  obligate  intracellular  bacte- 
rium  that  is  phagocytized by  and  resides  within 
mononuclear phagocytes. Previously we have demonstrated 
that complement receptors -- CPd and CR3 on monocytes 
and CR1,  CR3,  and CR4  on  monocyte-derived macro- 
phages- and fragments of complement C3 on the bacterial 
surface mediate phagocytosis  of M.  leprae (1, 2). 
The surface structure of M. leprae has been studied in de- 
tail and the major surface molecules have  been purified (3-6). 
Ultrastructural studies have suggested  that the cell wall of 
M. leprae has three layers- an electron dense innermost layer 
containing peptidoglycan (5); an electron-transparent middle 
layer composed of long chain mycocerosyl fatty acyl groups 
and arabinogalactan, an abundant polysaccharide ofM. leprae 
(4); and an outer layer composed largely of carbohydrates (6). 
These carbohydrates include the terminal saccharides of the 
phenolic glycolipidg the major glycolipid moieties of M. lelYrae; 
the terminal sugars of lipoarabinomannan (LAM)  1, the major 
1Abbreviations used in this ~per: DIM, dimycocemsyl-phthiocerol; HI, heat 
inactivated; LAM, lipoarabinomannan; LM, lipomannan; MOMP, major 
outer membrane protein; PGL-1, phenolic glycolipid-1. 
complex lipopolysaccharide  of M.  leprae; and lipomannan 
(LM), a molecule resembling LAM but devoid of arabinose 
moieties (4). Of the three closely related M. leprae phenolic 
glycolipids phenolic glycolipid-1 (PGI~I) a molecule found 
in enormous quantities in M. leprae-infected tissues, is by far 
the most abundant (7-9). The molecules in the outer layer 
of M. leprae are bdieved to be arrayed such that their carbo- 
hydrate moieties form the outermost coat of the bacterium. 
In this study, we have explored the capacity of molecules on 
the M. leprae surface to serve as acceptor molecules for the 
covalent linkage of C3 activation  products. 
Materials and Methods 
Mycobacterium leprae Components and mAbs Against them.  PGbl 
(8); LAM (10); arabinogalactan (11); monodeglycosylated  PGL-1 
(8); Mycoside B from MFobacterium bovis (12); dimycocerosyl- 
phthiocerol (DIM) (8); deacylated  PGbl (8); native trisaccharide 
-0- BSA (NT-O-BSA) (13); mouse  mAb (ascites) against PGL-1 (ML 
8B2) (14); and mouse mAb (asdtes) against LAM (ML 9D3) (15) 
were generously  provided  by Dr. Patrick Brennan and colleagues 
(Colorado State University, Fort Collins, CO) through the Na- 
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Sera.  Serum from four healthy adult volunteers who were PPD 
negative and had no known exposure to patients with leprosy was 
used in all experiments and obtained as described (16). 
Enzyme-lined Immunosorbent Assay (F.LISA) of C3 Fixation to 
Mycobacterium leprae Components.  Stock  PGL-1, monodeglyco- 
sylated PGbl, Mycoside B, DIM, and deacylated PGD1 (in chloro- 
form/methanol 2:1 v/v) were aliquoted in various amounts into 
borosilicate tubes and dried under Nz. The molecules were then 
resuspended in 100% ethyl alcohol by sonication in a sonic bath 
until dear. 50/zl of each solution, or ethyl alcohol only as a con- 
trol, was aliquoted into ELISA plate wells (Costar Corp.,  Cam- 
bridge, MA) and evaporated to dryness (2 h). Stock solutions of 
LAM, LM, arabinogalactan, and NT-O-BSA were further diluted 
to various concentrations in carbonate-bicarbonate buffer (0.05M, 
pH 9.6). 50/tl of each solution, or carbonate-bicarbonate buffer 
with or without BSA (ICN Immunobiologicals, Lisle, IL) as con- 
trois, was aliquoted in duplicate into ELISA plate wells, incubated 
at 37~  overnight on a shaking platform, and washed three times 
with PBS. From this point on, all ELISA plates were handled iden- 
tically. 
Nonspecific protein binding sites were blocked with PBS con- 
taining 5% HSA (Cat. no. 126658; Calbiochem Corp.,  La Jolla, 
CA) for 2 h at 37~  (shaking phtform at 40 rpm). The blocked 
wells were washed with PBS and incubated with various prepara- 
tions of 2.5% human serum or with PBS containing 0.5% HSA 
for 30 min at 37~  The wells were then washed five times in PBS 
(4~  and incubated with a primary antibody in 0.5% HSA or 
with 0.5% HSA alone as a control (overnight, 4~  Primary anti- 
bodies  were  chicken anti-human  C3  (Accurate Chemical  and 
Scientific Co.,  Westbury,  NY) diluted  1:10,000; mAb to C3bi 
(Cytotech, San Diego, CA) diluted 1:150,000, and mAbs to PGL-1 
and LAM diluted  1:800. The wells were washed three times in 
PBS, incubated with a HR.P-conjugated secondary antibody (goat 
anti-mouse IgG [Biorad, Richmond, CA] diluted 1:3000  or human 
absorbed goat anti-chicken IgG [Bethyl Labs, Inc., Montgomery, 
TX] diluted 1:5000) in 0.5% HSA for 2 h at room temperature, 
washed again, and incubated with HRP-substrate  (Bio-Rad) for 
10 min at room temperature. The reaction was stopped with 1% 
(final concentration) oxalic add. Absorbance at 405 nm was mea- 
sured. The mean  _+  SD of the absorbance for duplicate wells of 
each type was calculated. The optical density of control wells was 
subtracted out and was typically g0.10. 
Preparation ofPGL1-coated  Microspheres.  2.0  x  10  s Polybead 
polystyrene microspheres (Cat. number 07310; Polysciences,  Inc., 
Warrington,  PA), 1/~m in diameter, were washed two times in 
carbonate-bicarbonate buffer by centrifugation at 350 g for 5 min 
in presiliconized polypropylene tubes (Research Products, Mount 
Prospect, IL). The supemate was removed and the beads were in- 
cubated for 2 h at 37~  on a Adams Nutator (Clay Adams, Parsip- 
pan),, NJ) with PGbl (100 #g) that had been suspended in 1 ml 
of carbonate-bicarbonate buffer by sonication for 10 min with a 
3-mm sonicator probe. Control microspheres were incubated with 
carbonate-bicarbonate buffer alone. The microspheres were washed 
twice and then incubated in PBS containing 5% HSA for 2 h at 
37~  to block nonspedfic protein binding sites. The beads were 
then washed in PBS containing 0.5% HSA and incubated for 30 
min at 37~  in 500 ~1 of  2.5% fresh serum, 2.5% heat-inactivated 
(HI) serum (heated at 56~  for 30 min), or 0.5% HSA. Finally, 
the microspheres  were washed, resuspended  in 500 #1 of  0.5% HSA, 
and adjusted to 10S/m1. 
lmmunofluorescence Assay for Detection of C3 on Opsonized ])GL 
1-coated Microspheres.  PGL-1  coated microspheres (107), incubated 
in either 2.5% fresh serum or 0.5% HSA as above, were incubated 
with fluorescein-conjugated rabbit anti-human C3c (Dako Corp., 
Carpinteria, CA) (1:20 dilution) for 30 min at 37~  on a nutator. 
The beads were then washed in 0.5% HSA, resuspended in 50 #1 
of the same buffer, and examined on glass slides by fluorescence 
microscopy. 
Assays of Phagocytosis of PGLl-coated Microspheres.  Human 
mononudear ceils were isolated and plated on glass coverslips in 
monolayer culture as previously described (1, 17). The monocyte 
monolayers were then cultured in R.PMI containing 10% autolo- 
gous serum for 24 h, washed vigorously in KPMI, resuspended 
in RPMI-20 mM HEPES (Sigma Chemical Co., St. Louis, MO), 
and incubated with variously prepared microspheres (107) at 37~ 
in 5% CO2-95% air on a shaking platform (100 rpm).  After 60 
min,  the  monocytes  were  washed  to  remove  nonadherent 
microspheres and fixed in 10% formalin. The percentage of mono- 
cytes with 91 adherent microsphere and the mean number (_+ SD) 
of microspheres per monocyte on each of triplicate coverslips  were 
determined by counting a minimum of 100 consecutive monocytes 
per coverslip by phase contrast  microscopy. 
In studies to determine if polystyrene microspheres that adhere 
to monocytes are ingested, monocytes were plated on plastic cov- 
erslips as previously described (1). The adherence assay was per- 
formed as described above except that the number of microspheres 
added was  increased to 2.5  x  107 to optimize  conditions  for 
enumerating ingested microspheres. In addition, after the 60 min 
incubation period, the monocytes were washed and incubated for 
an additional 30 rain before fzxation and preparation for electron 
microscopy  (1). Greater than 50 consecutive  monocyte cross-sections 
were examined for each experimental condition. 
Results 
PGL1  Fixes Complement  Component  C3.  To determine 
if any of M. leprae's outermost surface molecules are capable 
of fixing C3, we developed a sensitive ELISA to assess C3 
fixation to purified M. lqrrae surface carbohydrates. This ELISA 
enabled us to quantify C3 fixation to M. leprae molecules in 
low  concentrations  of  serum.  Maximal  phagocytosis  of 
M,  leFrae by monocytes occurs in/>2.5%  serum  (1).  The 
choice of HSA as a blocking agent was critical in this ELISA 
as it decreased nonspecific binding of native C3 to negligible 
levels. 
PGbl fixed C3 avidly,  and it did so in a dose-dependent 
manner (Fig. 1). In contrast, LAM, LM, and arabinogalactan 
did not fix appreciable C3 in ELISA wells either at the doses 
shown in Fig.  1 or at higher or lower doses.  All carbohy- 
drates were efficiently adsorbed to the ELISA plate wells as 
determined by using mAbs against these molecules. There- 
fore, C3  fixation was  specific for PGbl in the ELISA. 
C3 fixation to PGbl was strictly dependent upon serum 
concentration; maximal amounts of C3 were deposited in 
t>2.5% fresh serum (Fig. 2). In these studies, in addition to 
using a polyclonal anti-C3 antibody, we used a mAb specific 
for the C3 activation product C3bi. This latter antibody does 
not recognize native C3. The results with the two primary 
antibodies were similar, i.e., both antibodies revealed a similar 
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Figure 1.  PGL-1  fixes complement component C3 to its surface whereas 
LAM, LM, and arabinogalactan do not. Purified M. leprae surface mole- 
cules in the amounts indicated were adhered to wells of an ELISA plate. 
The wells were blocked with 5% HSA in PBS, washed, incubated with 
2.5% fresh serum at 37~  for 30 min, washed again, and examined for 
C3 deposition using a primary polyclonal antibody against human C3 and 
an HR.P-conjugated secondary antibody. The wells were incubated for 10 
min with HRP substrate,  the reaction was terminated with 1% oxalic 
acid, and absorbance at 405 nm was measured. Data are the mean +  SD 
of duplicate measurements in one representative experiment. Absorbance 
in wells devoid of antigen was subtracted out in each case and was always 
g0.10 OD. 
dependence of C3 fixation to PGbl on serum concentration. 
This result provided further  evidence for the specificity of 
our assay in detecting C3 activation products. It also demon- 
strated that  at least a portion of C3 bound to PGL-1 is in 
the form of C3bi. To confirm that C3 fixation to PGL-1 was 
dependent upon heat-labile complement components in serum, 
we compared C3 fixation in fresh and HI serum.  In 2.5% 
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Figure 2.  C3 fixation to PGD1 is serum-dependent. PGbl (4.5  #g) 
was adhered to ELISA plate wells. The wells were blocked with 5% HSA 
and incubated with various amounts of fresh nonimmune serum as indi- 
cated for 30 min at 37~  Fixed C3 in the wells was probed with either 
a polyclonal antibody against C3 (dotted line) or a mAb against C3bi (solid 
line) as the primary antibody and detected as in the previous figure. Data 
are the mean _+  SD absorbance for duplicate wells in one representative 
experiment. The absorbance in wells devoid of antigen was subtracted out 
in each case. 
fresh serum,  significant amounts of C3 were fixed. In con- 
trast,  in 2.5%  HI serum,  C3 fixation was abolished. 
We next examined the roles of the classical and alternative 
complement pathways in mediating  C3 fixation to PGI.-1. 
Compared with the level in fresh serum, C3 fixation was abol- 
ished both in serum containing EGTA and MgClz, a condi- 
tion in which the classical  pathway but not the alternative 
pathway is inhibited  (18),  and in serum containing EDTA, 
a condition in which both pathways are inhibited (Fig.  3). 
The  amount  of PGbl  in ELISA plate wells,  assayed with 
a primary mAb against PGbl, was not affected by the pres- 
ence of EDTA or EGTA-MgC12.  These results indicate that 
C3 fixation to isolated PGI.-1 takes place by the classical com- 
plement  pathway. 
C3 Fixation to PGL-1 Is Dependent Upon PGL-I's Terminal 
Trisaccharide and Long-chain Fatty Acids.  PGL-1 consists of a 
phenolic phthiocerol core linked to a unique trisaccharide at 
one end (3-O-methylrhamnose,  2,3-di-O-methylrhamnose, 
and 3,6 di-O-methylglucose at the terminal position) and a 
mixture of long-chain mycocerosyl fatty acyl groups at the 
other  (Fig.  4). 
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Figure 3.  C3 fixation to PGL-1 is mediated by the classical pathway of 
complement activation. PGbl (4.5 #g) was adhered to ELISA plate wells 
and then incubated at 37~  for 30 min in 2.5% fresh serum, 2.5% fresh 
serum containing 10 mM EGTA and 7 mM MgC12, or 2.5% fresh serum 
containing 10 mM EDTA.  C3 fixation was detected using a polyclonal 
antibody against C3. Data are the mean  _+ SD absorbance for duplicate 
wells  in the one representative experiment. 
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Figure 4.  Structure of PGbl. "P,," represents a mixture of 2 of 3 long 
chain mycocerosyl fatty acyl groups. (Reproduced, with permission, from 
the Annu.  Rev. Microbiol.; Vol. 44,  1987, by Annual Reviews Inc.). 
C3 forms a covalent linkage to either hydroxyl or amino 
groups on appropriate acceptor molecules. As PGIA contains 
only hydroxyl groups, located on the carbohydrate moieties, 
we hypothesized that these hydroxyl groups were the acceptor 
sites for C3 on PGL-1 and that the carbohydrates were there- 
fore required for C3 fixation. To test this hypothesis,  we studied 
C3 fixation by PGD1 molecules whose terminal sugars were, 
in essence, sequentially removed (Fig. 5). Intact PGbl fixed 
significant amounts of C3.  In contrast,  when the terminal 
glucose of PGL-1 was removed (monodeglycosylated PGL-1), 
C3 fixation was markedly  reduced (57 _+ 4% SE, n=2); con- 
trol studies using a primary mAb against PGD1 indicated 
that comparable amounts of PGL-1 and monodeglycosylated 
PGL-1 were bound to ELISA plate wells. When the 2 distal 
sugars were removed from a surrogate PGL-1 molecule, Myco- 
side B, whose core structure and mycocerosyl acyl groups 
are identical to PGL-1, C3 fixation was reduced further (67 
+  5 %, SE, n = 2). Finally, when all 3 terminal sugars were 
removed from PGD1, C3 fixation to the remaining mole- 
cule, dimycocerosal  pthiocerol (DIM) was reduced to the back- 
ground level obtained with HI serum.  Thus, the terminal 
trisaccharide of PGL-1 appears to play a critical role in C3 
fixation. 
In the ELISA, isolated PGL-1 was capable of  both activating 
the complement cascade  and fixing C3. We hypothesized that 
the long chain mycocerosyl acyl groups, the major lipid por- 
tion of the molecule, may be involved in C3 activation. To 
test  this  hypothesis,  we studied  C3 fixation  to deacylated 
PGD1; a molecule in which the long chain mycocerosyl acyl 
groups have been removed but the terminal trisaccharide re- 
mains intact (8). Deacylated PGL-1 fixed C3 poorly despite 
having all 3 sugars present (Fig. 5). That deacylated PGD1 
bound efficiently to ELISA plate wells was confirmed with 
a primary mAb directed against the terminal trisaccharide 
of PGL-1. This result indicates that the lipid portion of  PGL-1 
plays a major role in influencing complement activation. 
We also evaluated the capacity of a synthetic glycolipo- 
protein,  NT-O-BSA, to fix C3.  This glycoprotein contains 
the native terminal trisaccharide of PGL-1 linked to BSA via 
a 8-methoxycarbonyloctyl chemical linker. As little as 0.5 #g 
of NT-O-BSA fixed significant C3.  The mean optical den- 
sity reading for C3 with 0.5/zg of NT-O-BSA was 0.42  -+ 
0.01 (SD,  n=2), 2.5-fold the level obtained with 0.5/zg of 
BSA alone (0.17  +  0.02).  Thus, the combination of BSA 
and the chemical linker appears to provide a suitable environ- 
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Figure 5.  C3 fixation to PGL-1 requires the presence  of its terminal trisac- 
charide and long chain fatty acids. Intact PGD1, monodeglycosylated  PGL-1 
(PGIA  lacking  the  terminal  sugar  of  the  trisacchadde,  3,6  di-O- 
methylghcose), Mycoside B (a surrogate PGD1 molecule lacking the two 
terminal sugars of the tdsaccharide), DIM (PGD1 lacking its terminal trisac- 
charide), or deacylated  PGIr  (PGL-1 minus its mycocerosyl  fatty acyl  groups) 
was adhered to ELISA plate wells (4.5/~g of each molecule). The wells 
were blocked with 5% HSA in PBS and incubated at 37~  for 30 rain 
in either 2.5% fresh serum or 2.5% HI serum as a control.  C3 fixation 
was detected using a polyclonal antibody against C3. Data are the mean 
-+  SD absorbance for duplicate wells in one representative experiment. 
Absorbance in control wells incubated in HI serum was subtracted out 
in each case. 
ment for both complement activation and C3 deposition to 
the trisaccharide moiety of PGbl. 
PGL-1 and C3 Mediate Ingestion of Polystyrene Microspheres 
by Human Monocytes.  To determine if C3 activation prod- 
ucts bound to PGbl can mediate phagocytosis, we studied 
the influence of PGbl and C3 on phagocytosis of inert parti- 
cles - polystyrene microspheres.  We preincubated microspheres 
with HSA before incubating them in serum to inhibit "back- 
ground" opsonization  in nonimmune serum. This allowed 
us specifically  to evaluate the role of PGI:I in mediating C3 
fixation to microspheres and adherence of opsonized micro- 
spheres to human monocytes. 
To  confirm  that  PGL-1 mediates  binding  of  C3  on 
microspheres, we examined the microspheres for C3 by im- 
munofluorescence microscopy. Whereas PGL-1 coated micro- 
spheres incubated  in fresh serum bound readily detectable 
amounts of C3, PGL-1 coated microspheres  incubated in buffer 
had no detectable C3. 
Precoating microspheres  with PGL-1 before incubating them 
in serum significantly increased their adherence to monocytes. 
Whereas,  34  _+  1% (mean _+  SE, n=2) of monocytes ad- 
hered/>1 PGL-1 coated microsphere, only 8  -+  1% adhered 
plain microspheres (Table 1). Even more striking, monocytes 
bound 10  _+  2-fold (mean _+  SE, n=2) more PGL-1 coated 
microspheres than plain microspheres (Table 1). Thus, PGL-1 
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monocytes. 
To determine if adherence of PGbl coated microspheres 
by monocytes requires C3 deposition onto their surface, we 
compared adherence of PGI.-1 coated microspheres incubated 
in fresh serum, conditions in which C3 is deposited, with 
adherence of PGL,1 coated microspheres incubated in HI serum 
or no serum, conditions under which C3 is not deposited. 
Compared with the level after incubation in fresh serum, ad- 
herence to monocytes of microspheres incubated in HI serum 
or no serum was dramatically reduced (84  _  6% reduction 
for HI serum and 83  _+  9% reduction for no serum, mean 
+  SE, n = 2; Table 2). Thus, monocytes adhere PGD1 coated 
microspheres only under conditions in which C3 is deposited. 
To determine if PGbl and C3 mediate ingestion of poly- 
styrene microspheres by monocytes, we studied uptake of the 
microspheres by electron microscopy. Monocytes avidly in- 
gested PGL-1 coated microspheres that we preincubated in 
fresh serum (Fig. 6); 47% of monocyte cross-sections con- 
tained i>1 microsphere in intracellular vacuoles (mean of 0.90 
microspheres per cross-section). In contrast, monocytes in- 
gested few PGbl coated microspheres that were preincubated 
in HI serum; only 6% of monocyte cross-sections contained 
>--1 intracellular microsphere (mean of 0.07 microspheres per 
cross-section). Similarly, monocytes ingested few uncoated 
microspheres that were preincubated in fresh serum; only 10% 
of  monocyte  cross-sections  contained  />1  intraceUular 
microspheres (mean of 0.12 microspheres per cross-section). 
Thus, PGL-1 and C3 mediate ingestion as well as attachment 
of polystyrene microspheres by human monocytes. 
Table  1.  PGL-1 Mediates Adherence of Opsonized Microspheres to Human Monocytes 
Monocytes with 
Microsphere  I>1 adherent  Microspheres/ 
Exp.  treatment  microsphere  monocyte 
Fold increase 
in adherence* 
go  mean  _+  SD 
A  PGL-1  33  1.47  _+  0.26 
None (Control)  7  0.18  _+  0.18 
B  PGL-1  35  1.71  _+  0.47 
None (Control)  9  0.15  __  0.09 
11 
In two independent  experiments,  PGL-1  coated  or plain microspheres  were incubated  in 2.5% fresh serum for 30 min at 37~  washed, and incubated 
with monocytes  for 1 h at 37~  The monocytes  were fixed and examined  by phase contrast microscopy, and the percentage  of monocytes  with 
;~1 adherent microsphere  and the number of adherent microspheres  per monocyte  were enumerated. A minimum of 100 consecutive  monocytes  on 
triplicate coverslips was counted for each treatment condition. 
* Fold increase in the mean number of microspheres/monocyte  for PGL-1 coated microspheres compared with plain microspheres. 
Table 2.  Adherence of PGL-I-Coated Microspheres to Human Monocytes Is Dependent upon Heat-labik  Serum  Components 
Monocytes with 
91 adherent  Microspheres/  Decrease in 
Exp.  Serum  microsphere  monocyte  adherence" 
A 
go  mean  _+  SD  go 
Fresh  64  5.04  _+  0.69 
HI  15  0.50  +  0.07  90 
None  15  0.42  +  0.02  92 
Fresh  63  4.20  _+  0.40 
HI  26  0.91  +  0.33  78 
None  36  1.10  _+  0.19  74 
In two independent  experiments,  PGL coated  microspheres  were incubated in 2.5% fresh serum, 2.5% HI serum, or no serum for 30 min at 37~ 
vigorously washed, and incubated with monocytes  for 1 h at 37~  The monocytes  were fixed and examined by phase contrast microscopy,  and 
monocyte-adherent  microspheres  enumerated. A minimum of 100 consecutive  monocytes  on triplicate  coverslips  was counted  for each serum condition. 
* Percent decrease in the mean number of microspheres/monocyte  compared with the level in fresh serum. 
1035  Schlesinger  and Horwitz Figure 6.  PGL-1  and C3 mediate ingestion of polystyrene microspheres by human monocytes.  Monocytes in monolayer culture were incubated with 
polystyrene microspheres  that had been precoated with PGbl and incubated in fresh serum as described in the text. The monocytes were then washed, 
fixed, and prepared for electron microscopy.  (,4) The monocyte has ingested at least 4 microspheres  (arrows) (x9,700).  The clear areas are artifacts 
due to contraction of the microspheres  during processing.  (B) At higher magnification, a representative  microsphere is found in a membrane-bound 
vacuole  (x 36,000). 
Discussion 
Our studies have identified a three-component receptor- 
ligand-acceptor molecule system for mediating phagocytosis 
of M.  leprae.  This system consists  of complement receptors 
(CIL1 and CK3 on monocytes, and CK1, CR3, and CK4 
on monocyte-derived macrophages), fragments of comple- 
ment component C3,  and PGL-1. 
Complement receptors play a general role in mediating 
phagocytosis of a diverse group of intraceUular pathogens. 
Ligation of complement receptors by C3 does not trigger 
an appreciable oxidative burst, and thus these receptors may 
provide these intracellular pathogens safe passage into host 
cells. In this regard, ingestion of M.  leprae by mononudear 
phagocytes is not accompanied by a significant oxidative burst 
(19). Interestingly, PGL-1, adhered diffusely to the extracel- 
lular bacterium Staphylococcus  aureus, inhibited killing of this 
organism by macrophages in a previous study (20).  While 
other attributes of PGbl, such as a capacity to scavenge free 
radicals, may have contributed to its protective effect, it is 
also possible that the PGL-1 coat on S. aureus directed entry 
of the bacterium into macrophages via complement  receptors 
and allowed the bacterium to escape the toxic consequences 
of the oxidative burst. 
PGL,1 is found in abundance on M.  leprae (9, 21, 22), and 
it is arrayed such that its terminal trisaccharide,  the portion 
of the molecule available for covalent linkage to C3, is ex- 
posed  at  the  outermost surface.  Thus,  PGL-1 is  situated 
optimally for  mediating C3  fixation and phagocytosis of 
M.  leprae. 
PGL1, and not the other major carbohydrates ofM. leprae, 
was  found to  deposit significant  C3  on its  surface.  It  is 
noteworthy that LAM did not fix C3 in our assay, as it is 
the major lipopolysaccharide  ofM. leprae and is also located 
on the outer surface of the bacterium. This finding is reminis- 
cent of previous work demonstrating that the major outer 
membrane protein (MOMP) but not the LPS of Legionella 
tmeumophila  fixes C3 to this intracellular bacterium (23). PGbl 
and MOMP have in common that they are major constitu- 
ents of the outer surface of these microbes. 
Our study demonstrates that C3 fixation to PGD1 is de- 
pendent upon PGDI's terminal trisaccharide.  Complement 
activation by lipids in liposome models is also enhanced by 
short  chain saccharide  moieties (24).  Schultz et  al.  (25), 
studying the role of saccharide chain length in complement 
activation, determined that 3 saccharide moieties, but not 
1, 2, or 4, were required for efficient C1 activation and C4 
consumption. Thus, the capacity for PGL-1 to fax C3 may 
derive in part from the fact that its distal oligosaccharide  is 
a trisaccharide. 
Deacylated  PGbl fixed C3 poorly in our ELISA. As the 
lipid portion of PGL-1 possesses no suitable acceptor region 
for covalent linkage to the reactive thiolester of C3, this por- 
tion of the molecule may serve to orient the trisaccharide 
on the ELISA plate (or on a lipid membrane) so as to max- 
imize complement activation and C3 fixation.  Along these 
lines, in this study, the trisaccharide  of PGL-1 also fixed C3 
when linked via a chemical carrier  to BSA (NT-O-BSA). 
Schultz et al. studied complement activation by a different 
trisaccharide linked to BSA via the same chemical cartier (25). 
These authors showed that the trisaccharide activated the com- 
plement cascade when linked to BSA via the chemical carrier 
but not when linked directly to BSA. Thus, the chemical 
carrier may allow for proper orientation of the trisaccharide 
for complement activation. 
Our studies demonstrate that optimal C3 fixation to PGL-1 
requires both the terminal trisaccharide and the mycocerosyl 
fatty acyl side chains. That different portions of a molecule 
influence complement activation has been extensively studied 
with LPS molecules from gram-negative bacteria (26,  27). 
These studies have demonstrated that complement activation 
is dependent upon both the carbohydrate portion of the mol- 
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O-antigens influences the pathway of complement activation 
and can modify the complement  activity of Lipid A. 
Our studies demonstrate that activation of C3 in nonim- 
mune serum by isolated PGL-1 occurs by the classical com- 
plement pathway. In ongoing experiments,  we have found 
that, at low serum concentrations, comparable to those used 
in this study, a substantial proportion of C3 fixation to whole 
M.  leprae occurs by the classical  pathway.  Consistent  with 
this, these studies indicate that Clq binds avidly to M. Ieprae 
and PGbl. Interestingly, these studies also indicate that C3 
fixation and Clq binding  to M,  leprae and PGL-1  are trig- 
gered by extremely small amounts of cross-reactive (natural) 
antibody (either IgM or IgG) in nonimmune serum. Impor- 
tantly, although these studies have determined that relatively 
more antibody in nonimmune  serum binds to LAM, LM, 
and arabinogalactan  than to PGbl, only PGL,1 fixes appreciable 
amounts of C3, underscoring the selectivity of C3 fixation 
to PGL-1. 
Understanding the molecular basis for phagocytosis of in- 
tracellular parasites may not only yield new insights into the 
pathogenesis of intracellular parasitism but also point to new 
strategies for interfering with the life cycle of these organisms. 
This in turn may lead to the development of new modalities 
for preventing and treating diseases caused by this important 
group of pathogens. 
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